Caprelsa Prices, Coupons, Copay Cards & Patient Assistance
Caprelsa (vandetanib) is a member of the EGFR inhibitors drug class and is commonly used for Thyroid Cancer.
The cost for Caprelsa 100 mg oral tablet is around $9,482 for a supply of 30 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Caprelsa is available as a brand name drug only, a generic version is not yet available. View generic Caprelsa availability for more details.
Caprelsa prices
Oral Tablet
100 mg
Caprelsa oral tablet
from $9,482.32
for 30 tablets
Quantity | Per unit | Price |
---|---|---|
30 | $316.08 | $9,482.32 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
300 mg
Caprelsa oral tablet
from $18,954.63
for 30 tablets
Quantity | Per unit | Price |
---|---|---|
30 | $631.82 | $18,954.63 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Caprelsa Coupons, Copay Cards and Rebates
Caprelsa offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Caprelsa Co-Pay Assistance Program
Eligible commercially insured patients may save on out-of-pocket costs over $50 up to the program maximum each calendar year.
- Applies to:
- Caprelsa
- Number of uses:
- Per prescription per calendar year
Form more information phone: 800-367-4999 or Visit website
Caprelsa Interim Access Program
Eligible commercially insured patients who are experiencing a delay in their coverage may be able to receive a short term supply of medication free of charge.
- Applies to:
- Caprelsa
- Number of uses:
- Temporary Assistance
Form more information phone: 800-367-4999 or Visit website
Patient Assistance & Copay Programs for Caprelsa
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Caprelsa Patient Assistance Program
Eligibility requirements:- Must be uninsured or underinsured
- Not disclosed
- FDA-approved diagnosis
- The patient must also be permanently residing in the US or US territories.
- Prescribing Physician, Healthcare Facilities, Pharmacies and Patients must enroll into the Risk Evaluation and Mitigation Strategy (REMS) Program prior to initiating the patient on treatment with Caprelsa. Co-payment assistance, reimbursement support, and patient assistance programs are available for eligible patients.
- Caprelsa (vandetanib) Tablet
More information please phone: 800-367-4999 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Caprelsa (vandetanib)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- Breastfeeding
- En español